Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Concert Pharmaceuticals Inc.
DescriptionOral deuterium-modified ruxolitinib, a Janus kinase-1 (JAK-1) and JAK-2 inhibitor
Molecular Target Janus kinase-1 (JAK-1) ; Janus kinase-2 (JAK-2)
Mechanism of ActionJanus kinase-2 (JAK-2) inhibitor; Janus kinase-1 (JAK-1) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard Indication Autoimmune (unspecified)
Indication DetailsTreat alopecia areata
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today